Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Alzheimer`s Disease Neuroimaging Initiative Grand Opportunity


Alzheimer`s Disease Neuroimaging Initiative Grand Opportunity




The purpose of this study is to build upon the information obtained in the original Alzheimer`s Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer`s disease (AD). ADNI-GO seeks to define and characterize the mildest symptomatic phase of AD, referred to in this study as early amnestic MCI (EMCI). This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Study Status: Completed


Condition Intervention Phase
Mild Cognitive Impairment
Alzheimer`s Disease
n/a N/A

Verified by Alzheimer`s Disease Cooperative Study (ADCS) May, 2013

Sponsored by: Alzheimer`s Disease Cooperative Study (ADCS)
Information provided by: Alzheimer`s Disease Cooperative Study (ADCS) identifier: NCT01078636

Study Type: Interventional

Study Design: Observational Model: Case Control, Time Perspective: Prospective

Cleveland Clinic Lou Ruvo Center for Brain Health (CCLRBC)
Las Vegas, Nevada 89106
United States

Ronald Petersen, MD, PhD., Study Chair
Michael W Weiner, MD., Principal Investigator
Paul Aisen, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site